{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:06:22Z","timestamp":1793829982451,"version":"4.6.1"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"Introduction<\/jats:title>In one third of all patients with epilepsy, seizure freedom is not achieved through anti-seizure medication (ASM). These patients have an increased risk of earlier death, poorer cognitive development, and reduced quality of life. Cenobamate (CNB) has recently been approved as a promising novel ASM drug for the treatment of adults with focal-onset epilepsy. However, there is little experience for its application in pediatric patients.<\/jats:p><\/jats:sec>Methods<\/jats:title>In a multicenter study we evaluated retrospectively the outcome of 16 pediatric patients treated \u201coff label\u201d with CNB.<\/jats:p><\/jats:sec>Results<\/jats:title>In 16 patients with a mean age of 15.38 years, CNB was started at an age of 15.05 years due to DRE. Prior to initiation of therapy, an average of 10.56 (range 3\u201320) ASM were prescribed. At initiation, patients were taking 2.63 (range 1\u20134) ASM. CNB was increased by 0.47 \u00b1 0.27mg\/kg\/d every 2 weeks with a mean maximum dosage of 3.1 mg\/kg\/d (range 0.89\u20137) and total daily dose of 182.81 mg (range 50\u2013400 mg). Seizure freedom was achieved in 31.3% and a significant seizure reduction of &gt;50% in 37.5%. Adverse events occurred in 10 patients with fatigue\/somnolence as the most common. CNB is taken with high adherence in all but three patients with a median follow-up of 168.5 days<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Cenobamate is an effective ASM for pediatric patients suffering from drug-resistant epilepsy. In addition to excellent seizure reduction or freedom, it is well-tolerated. Cenobamate should be considered as a novel treatment for DRE in pediatric patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.950171","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T07:19:43Z","timestamp":1657610383000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["Real-World Experience Treating Pediatric Epilepsy Patients With Cenobamate"],"prefix":"10.3389","volume":"13","author":[{"given":"Konstantin L.","family":"Makridis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Prager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Kovacevic-Preradovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Bittigau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Kaindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1684\/epd.2015.0736","article-title":"Incidence, prevalence and aetiology of seizures and epilepsy in children","volume":"17","author":"Camfield","year":"2015","journal-title":"Epileptic Disorders."},{"key":"B2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","article-title":"Patterns of treatment response in newly diagnosed epilepsy","volume":"78","author":"Brodie","year":"2012","journal-title":"Neurology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1212\/WNL.0000000000001005","article-title":"Epilepsy-related clinical characteristics and mortality: a systematic review and meta-analysis","volume":"83","author":"Nevalainen","year":"2014","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","article-title":"The consequences of refractory epilepsy and its treatment","volume":"37","author":"Laxer","year":"2014","journal-title":"Epilepsy Behav."},{"key":"B6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.seizure.2022.02.009","article-title":"Epilepsy surgery in the first six months of life: a systematic review and meta-analysis","volume":"96","author":"Makridis","year":"2022","journal-title":"Seizure."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2022.1436.","article-title":"Ictal EEG recording is not mandatory in all candidates for paediatric epilepsy surgery with clear MRI lesions and corresponding seizure semiology","author":"Makridis","year":"","journal-title":"Epilept Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug\u2013drug interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs."},{"key":"B9","doi-asserted-by":"publisher","first-page":"173117","DOI":"10.1016\/j.ejphar.2020.173117","article-title":"Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate","volume":"879","author":"Sharma","year":"2020","journal-title":"Eur J Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur J Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1111\/epi.17091","article-title":"Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study","volume":"62","author":"Sperling","year":"2021","journal-title":"Epilepsia."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.950171\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T08:36:12Z","timestamp":1658392572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.950171\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":12,"alternative-id":["10.3389\/fneur.2022.950171"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.950171","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"article-number":"950171"}}